Nilotinib companion diagnostic - Novartis

Drug Profile

Nilotinib companion diagnostic - Novartis

Alternative Names: MRDx BCR-ABL

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic myeloid leukaemia

Most Recent Events

  • 04 Jun 2018 Nilotinib companion diagnostic licensed to Genoptix for commercialisation in USA for the Chronic myeloid leukaemia (Diagnosis)
  • 22 Dec 2017 The US FDA approves nilotinib companion diagnostic for treatment-free remission in Philadelphia chromosome positive (Ph+) patients with Chronic myeloid leukaemia
  • 19 Feb 2014 Novartis and MolecularMD agree to co-develop Nilotinib companion diagnostic test for Chronic myeloid leukaemia (diagnosis)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top